Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer
- 20 December 1990
- journal article
- review article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 37 (6) , 1037-1041
- https://doi.org/10.1016/0960-0760(90)90462-t
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancerBritish Journal of Cancer, 1990
- Suppression of Postmenopausal Ovarian Steroidogenesis With the Luteinizing Hormone-Releasing Hormone Agonist Goserelin*Journal of Clinical Endocrinology & Metabolism, 1988
- A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patientsBritish Journal of Cancer, 1985
- LOW-DOSE AMINOGLUTETHIMIDE IN TREATMENT OF ADVANCED BREAST CANCERThe Lancet, 1984
- EFFECTS OF AMINOGLUTETHIMIDE ON ADRENAL STEROID SECRETIONClinical Endocrinology, 1983
- Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancerBritish Journal of Cancer, 1983
- Endocrine and Therapeutic Effects of Aminoglutethimide in Premenopausal Patients with Breast CancerJournal of Clinical Endocrinology & Metabolism, 1982
- Inhibition of Estrogen Biosynthesis and Regression of Mammary Tumors by Aromatase InhibitorsPublished by Springer Nature ,1982
- Resistance of the Ovary to Blockade of Aromatization with Aminoglutethimide*Journal of Clinical Endocrinology & Metabolism, 1980
- Aminoglutethimide Inhibits Extraglandular Estrogen Production in Postmenopausal Women with Breast Carcinoma*Journal of Clinical Endocrinology & Metabolism, 1978